Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Kim T, Brinker A, Croteau D, Lee PR, Baldassari LE, Stevens J, Hughes A, Tomaino J, deFonseka A, Altepeter T, Kortepeter CM.
Kim T, et al. Among authors: croteau d.
Mult Scler. 2023 Sep;29(10):1275-1281. doi: 10.1177/13524585231195854.
Mult Scler. 2023.
PMID: 37706451
Review.